Rallybio has swerved away from its Recursion Pharmaceuticals pact, accepting $7.5 million upfront for its share of a preclinical program to extend its cash runway to mid-2027.
Exscientia, now part of Recursion, partnered with Rallybio in 2019 to develop small-molecule treatments for rare diseases. The alliance spawned REV102, an…
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks
OWL Planners Officially Launches the OWL Planner™, Simplifying Next-of-Kin Preparation and Essential Document Storage
SALT LAKE CITY, Feb. 20, 2025 /PRNewswire/ — OWL Planners, a Utah-based company, is excited to announce the official launch of its new range of essential document storage and next-of-kin preparation products. OWL Planners aims […]
ViaLase and the John A. Moran Eye Center Announce Research Partnership to Accelerate Glaucoma Research and Innovation
ALISO VIEJO, Calif.–(BUSINESS WIRE)– #MoranEyeCenter–ViaLase, Inc., a clinical-stage medical technology company focused on addressing unmet needs in the conventional glaucoma treatment paradigm, today announced a research partnership with the John A. Moran Eye Center at […]
Plexus Worldwide® Contributes 22,500 Meals to Salt Lake City Through Volunteer Initiative
Part of the company’s ongoing commitment to fighting hunger, the volunteer day included more than 50 local Brand Ambassadors and a $5,000 donation to Utah Food Bank SCOTTSDALE, Ariz., June 9, 2023 /PRNewswire/ — Plexus […]
